SRC kinase-mediated signaling pathways and targeted therapies in breast cancer

Breast Cancer Res. 2022 Dec 29;24(1):99. doi: 10.1186/s13058-022-01596-y.

Abstract

Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor tyrosine kinase (nRTK) family, which has eleven members sharing similar structure and function. Among them, SRC is the first identified proto-oncogene in mammalian cells. Oncogenic overexpression or activation of SRC has been revealed to play essential roles in multiple events of BC progression, including tumor initiation, growth, metastasis, drug resistance and stemness regulations. In this review, we will first give an overview of SRC kinase and SRC-relevant functions in various subtypes of BC and then systematically summarize SRC-mediated signaling transductions, with particular emphasis on SRC-mediated substrate phosphorylation in BC. Furthermore, we will discuss the progress of SRC-based targeted therapies in BC and the potential future direction.

Keywords: Breast cancer; SRC kinase; Signaling transduction; Targeted therapy; Tyrosine phosphorylation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Female
  • Humans
  • Phosphorylation
  • Signal Transduction
  • src-Family Kinases* / genetics
  • src-Family Kinases* / metabolism

Substances

  • src-Family Kinases